Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ · Healthcare
Ultragenyx Pharmaceutical Inc. Operating Income 2016–2025
Ultragenyx Pharmaceutical Inc. annual/quarterly operating income history and growth rate from 2016 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Ultragenyx Pharmaceutical Inc. operating income for the quarter ending March 31, 2026 was -169.0 M, a 18.18% increase year-over-year.
- Ultragenyx Pharmaceutical Inc. operating income for the twelve months ending March 31, 2026 was -590.8 M, a 5.72% increase year-over-year.
- Ultragenyx Pharmaceutical Inc. annual operating income for 2025 was -535.0 M, a 0.19% decrease from 2024.
- Ultragenyx Pharmaceutical Inc. annual operating income for 2024 was -536.0 M, a 5.80% decrease from 2023.
- Ultragenyx Pharmaceutical Inc. annual operating income for 2023 was -569.0 M, a 12.32% decrease from 2022.
- Ultragenyx Pharmaceutical Inc. annual operating income for 2022 was -648.9 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Ultragenyx Pharmaceutical Inc. Operating Income — FAQ
Ultragenyx Pharmaceutical Inc. (RARE) operating income over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
What is Ultragenyx Pharmaceutical Inc.'s operating income?
Ultragenyx Pharmaceutical Inc. (RARE) reported operating income of -$535M for fiscal 2025.
Where can I see RARE's operating income history?
The chart and table above show Ultragenyx Pharmaceutical Inc.'s operating income by year and by quarter, including the growth rate.